Tirzepatide lowered risk of worsening heart failure and CVD death for obese adults
In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...
News Medical6h
Tirzepatide improves heart health and function in obese HFpEF patients
In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...
Eli Lilly’s tirzepatide cuts risk of worsening heart failure in HFpEF, obese patients
Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...